Pathophysiology of cyclooxygenase inhibition in animal models

Toxicologic Pathology

Volumn 37, Issue 1, 2009, Pages 34-46

  Radi, Zaher A ^a  

^a PFIZER INC   (United States)

Author keywords

Bone; Cyclooxygenases; Eye; Gastrointestinal tract; Pathophysiology; Renal

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CARPROFEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; ELECTROLYTE; FIROCOXIB; FLUNIXIN MEGLUMINE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOROLAC; LUMIRACOXIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PHENYLBUTAZONE; PROSTAGLANDIN; PROSTAGLANDIN E2; ROFECOXIB; SULINDAC; SUPROFEN; TENOXICAM; UNCLASSIFIED DRUG; VALDECOXIB; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; BLOOD PRESSURE REGULATION; CONTINUOUS INFUSION; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM ULCER; DISEASE PREDISPOSITION; DRUG MEGADOSE; ENZYME INHIBITION; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; GASTROINTESTINAL TOXICITY; GLAUCOMA; HORSE; HUMAN; HYPERTENSION; KERATITIS; LIGAMENT INJURY; MIOSIS; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHOTOPHOBIA; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; RETROLENTAL FIBROPLASIA; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; SPECIES DIFFERENCE; TENDON INJURY; UVEA DISEASE; UVEITIS; WOUND HEALING IMPAIRMENT; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOG; DRUG EFFECT; ENZYMOLOGY; EYE; FRACTURE HEALING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; INJURY; INTESTINE MUCOSA; KIDNEY; LIGAMENT; METABOLISM; PATHOLOGY; PHYSIOLOGY; RAT;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

ANIMALS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DOGS; EYE; FRACTURE HEALING; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; INTESTINAL MUCOSA; KIDNEY; LIGAMENTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; TENDON INJURIES;

EID: 62749132930     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623308329474     Document Type: Review

References (172)

1. Adamis, AP, JW Miller, MT Bernal, DJ D'Amico, J Folkman, TK Yeo, and KT Yeo (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol, 118, 445-450.
2. Adamis, AP (2002). Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol, 86, 363-365.
3. Adams, SS, RG Bough, EE Cliffe, B Lessel, and RF Mills (1969). Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol, 15, 310-330.
4. Aiello, LP, RL Avery, PG Arrigg, BA Keyt, HD Jampel, ST Shah, LR Pasquale, H Thieme, MA Iwamoto, and JE Park (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med, 331, 1480-1487.
5. Allen, HL, A Wase, and WT Bear (1980). Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat. Acta Orthop Scand, 51, 595-600.
6. Altman, RD, LL Latta, R Keer, K Renfree, FJ Hornicek, and K Banovac (1995). Effect of nonsteroidal antiinflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma, 9, 392-400.
7. Altinkaynak, K, H Suleyman, and F Akcay (2003). Effect of nimesulide, rofecoxib and celecoxib on gastric tissue glutathione level in rats with indomethacin-induced gastric ulcerations. Pol J Pharmacol, 55, 645-648.
8. Arai, I, Y Hamasaka, N Futaki, S Takahashi, K Yoshikawa, S Higuchi, and S Otomo (1993). Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res Commun Chem Pathol Pharmacol, 81, 259-270.
9. Ayalasomayajula, SP, AC Amrite, and UB Kompella (2004). Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol, 498, 275-278.
10. Ayalasomayajula, SP, and UB Kompella (2003). Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol, 458, 283-289.
11. Ayalasomayajula, SP, and UB Kompella (2004). Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res, 21, 1797-1804.
12. Beck, A, G Krischak, T Sorg, P Augat, K Farker, U Merkel, L Kinzl, and L Claes (2003). Influence of diclofenac (group of nonsteroidal anti-inflammatory drugs) on fracture healing. Arch Orthop Trauma Surg, 123, 327-332.
13. Black, SC, C Brideau, M Cirino, M Belley, J Bosquet, CC Chan, and IW Rodger (1998). Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs. J Cardiovasc Pharmacol, 32, 686-694.
14. Blanco-Rivero, J, V Cachofeiro, V Lahera, R Aras-Lopez, I Marquez-Rodas, M Salaices, FE Xavier, M Ferrer, and G Balfagon (2005). Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension, 46, 107-112.
15. Blumberg, AL, SE Denny, GR Marshall, and P Needleman (1977). Blood vessel-hormone interactions: angiotensin, bradykinin, and prostaglandins. Am J Physiol, 232, H305-310.
16. Boiskin, I, S Epstein, F Ismail, MD Fallon, and W Levy (1988). Long term administration of prostaglandin inhibitors in vivo fail to influence cartilage and bone mineral metabolism in the rat. Bone Miner, 4, 27-36.
17. Bonazzi, A, V Mastyugin, PA Mieyal, MW Dunn, and M Laniado-Schwartzman (2000). Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium. J Biol Chem, 275, 2837-2844.
18. Brands, MW, AE Hailman, and SM Fitzgerald (2001). Long-term glucose infusion increases arterial pressure in dogs with cyclooxygenase-2 inhibition. Hypertension, 37, 733-738.
19. Brown, KM, MM Saunders, T Kirsch, HJ Donahue, and JS Reid (2004). Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am, 86-A, 116-123.
20. Castro, MR, D Lutz, and JL Edelman (2004). Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res, 79, 275-285.
21. Cheng, T, W Cao, R Wen, RH Steinberg, and MM LaVail (1998). Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci, 39, 581-591. (Pubitemid 28110692)
22. Cheng, HF, JL Wang, MZ Zhang, SW Wang, JA McKanna, and RC Harris (2001). Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol, 280, F449-F456.
23. Collins, LG, and DE Tyler (1985). Experimentally induced phenylbutazone toxicosis in ponies: description of the syndrome and its prevention with synthetic prostaglandin E2. Am J Vet Res, 46, 1605-1165.
24. Coppelli, G, E Guaita, S Spaggiari, and G Coruzzi (2004). Gastric effects of the selective cyclooxygenase-2 inhibitor, celecoxib, in the rat. Digest Liver Dis, 36, 265-270.
25. Cosenza, SF (1984). Drug-induced gastroduodenal ulceration in dogs. Modern Vet Pract, 65, 923-925.
26. Court, MH, and DJ Greenblatt (1997). Molecular basis for deficient acet-aminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochem Pharmacol, 53, 1041-1047.
27. Cursiefen, C, C Rummelt, and M Kuchle (2000). Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and ransforming growth factor beta1 in human corneas with neovascularization. Cornea, 19, 526-533.
28. Cuzzocrea, S, E Mazzon, I Serraino, L Dugo, T Centorrino, A Ciccolo, L Sautebin, and AP Caputi (2001). Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol, 431, 91-102.
29. Daehler, MH (1986). Transmural pyloric perforation associated with naproxen administration in a dog. J Am Vet Med Assoc, 189, 694-695.
30. de Leeuw, PW (1996). Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective. Drugs, 51, 179-187.
31. Dinchuk, JE, BD Car, RJ Focht, JJ Johnston, BD Jaffee, MB Covington, NR Contel, VM Eng, RJ Collins, and PM Czerniak (1995). Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature, 378, 406-409.
32. Doucet, MY, AL Bertone, D Hendrickson, F Hughes, C Macallister, S McClure, C Reinemeyer, Y Rossier, R Sifferman, AA Vrins, G White, B Kunkle, R Alva, D Romano, and PD Hanson (2008). Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. J Am Vet Med Assoc, 232, 91-97.
33. Duggan, DE, KF Hooke, RM Noll, and KC Kwan (1975). Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol, 24, 1749-1754.
34. Elliott, GA, A Purmalis, DA Vandermeer, and RH Denlinger (1988). The propionic acids. Gastrointestinal toxicity in various species. Toxicol Pathol, 16, 245-250.
35. Elliott, SL, RJ Ferris, AS Giraud, GA Cook, MV Skeljo, and ND Yeomans (1996). Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol, 23, 432-434.
36. Ewing, GO (1972). Indomethacin-associated gastrointestinal hemorrhage in a dog. J Am Vet Med Assoc, 161, 1665-1668.
37. Feyen, JH, G van der Wilt, P Moonen, A Di Bon, and PJ Nijweide (1984). Stimulation of arachidonic acid metabolism in primary cultures of osteoblast-like cells by hormones and drugs. Prostaglandins, 28, 769-781.
38. Forsyth, SF, WG Guilford, SJ Haslett, and J Godfrey (1998). Endoscopy of the gastroduodenal mucosa after carprofen, meloxicam and ketoprofen administration in dogs. J Small Anim Pract, 39, 421-424.
39. Forwood, MR (1996). Inducible cyclooxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res, 11, 1688-1693.
40. Frank, RN (2004). Diabetic retinopathy. N Engl J Med, 350, 48-58.
41. Frucht, J, and H Zauberman (1984). Topical indomethacin effect on neovascularisation of the cornea and on prostaglandin E2 levels. Br J Ophthalmol, 68, 656-659.
42. Gajraj, NM (2003). The effect of cyclooxygenase-2 inhibitors on bone healing. Reg Anesth Pain Med, 28, 456-465.
43. Gardiner, TA, HR Anderson, T Degenhardt, SR Thorpe, JW Baynes, DB Archer, and AW Stitt (2003). Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug. Diabetologia, 46, 1269-1275.
44. Gaynes, BI, and R Fiscella (2002). Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf, 25, 233-250.
45. Gerstenfeld, LC, M Al-Ghawas, YM Alkhiary, DM Cullinane, EA Krall, JL Fitch, EG Webb, MA Thiede, and TA Einhorn (2007). Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. J Bone Joint Surg Am, 89, 114-125.
46. Gerstenfeld, LC, DM Cullinane, GL Barnes, DT Graves, and TA Einhorn (2003). Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. J Cell Biochem, 88, 873-884.
47. Giordano, V, M Giordano, IG Knackfuss, MI Apfel, and RD Gomes (2004). Effect of tenoxicam on fracture healing in rat tibiae. Injury, 34, 85-94.
48. Giuliano, EA (2004). Nonsteroidal anti-inflammatory drugs in veterinary ophthalmology. Vet Clin North Am Small Anim Pract, 34, 707-723.
49. Godshalk, CP, JK Roush, RB Fingland, D Sikkema, and MW Vorhies (1992). Gastric perforation associated with administration of ibuprofen in a dog. J Am Vet Med Assoc, 201, 1734-1736.
50. Goodman, S, T Ma, M Trindade, T Ikenoue, I Matsuura, N Wong, N Fox, M Genovese, D Regula, and RL Smith (2002). COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res, 20, 1164-1169.
51. Gregory, LS, and MR Forwood (2007). Cyclooxygenase-2 inhibition delays the attainment of peak woven bone formation following four-point bending in the rat. Calcif Tissue Int, 80, 176-183.
52. Gross, JM, JE Dwyer, and FG Knox (1999). Natriuretic response to increased pressure is preserved with COX-2 inhibitors. Hypertension, 34, 1163-1167.
53. Hallesy, DW, LD Shott, and R Hill (1973). Comparative toxicology of naproxen. Scand J Rheumatol (Suppl 2). 20-28.
54. Hao, CM, and MD Breyer (2008). Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol, 70, 357-377.
55. Hawkey, CJ, and MM Skelly (2002). Gastrointestinal safety of selective COX-2 inhibitors. Curr Pharm Des, 8, 1077-1089.
56. Ho, ML, JK Chang, and GJ Wang (1998). Effects of ketorolac on bone repair: A radiographic study in modeled demineralized bone matrix grafted rabbits. Pharmacology, 57, 148-159.
57. Hocherl, K, D Endemann, MC Kammerl, HF Grobecker, and A Kurtz (2002). Cyclooxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol, 136, 1117-1126.
58. Houston, MC (1991). Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med, 90, 42S-47S.
59. Jaffré, B, A Watrin, D Loeuille, P Gillet, P Netter, P Laugier, and A Saïed (2003). Effects of antiinflammatory drugs on arthritic cartilage: a high-frequency quantitative ultrasound study in rats. Arthritis Rheum, 48, 1594-1601.
60. Jee, WS, and YF Ma (1997). The in vivo anabolic actions of prostaglandins in bone. Bone, 21, 297-304.
61. Johnston, SA, and SC Budsberg (1997). Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Vet Clin North Am Small Anim Pract, 27, 841-862.
62. Karachalios, T, L Boursinos, L Poultsides, L Khaldi, and KN Malizos (2007). The effects of the short-term administration of low therapeutic doses of anti-COX-2 agents on the healing of fractures. An experimental study in rabbits. J Bone Joint Surg Br, 89, 1253-1260.
63. Kauffman, G (1989). Aspirin-induced gastric mucosal injury: lessons learned from animal models. Gastroenterology, 96, 606-614.
64. Kawaguchi, H, CC Pilbeam, JR Harrison, and LG Raisz (1995). The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res, 313, 36-46.
65. Keller, J, C Bunger, TT Andreassen, B Bak, and U Lucht (1987). Bone repair inhibited by indomethacin. Effects on bone metabolism and strength of rabbit osteotomies. Acta Orthop Scand, 58, 379-383.
66. Keller, J, ES Hansen, SZ He, P Kjaersgaard-Andersen, and C Bunger (1991). Early hemodynamic response to tibial osteotomy in rabbits: influence of indomethacin and prostaglandin E2. J Orthop Res, 9, 539-544.
67. Keller, J, A Klamer, B Bak, and P Suder (1993). Effect of local prostaglandin E2 on fracture callus in rabbits. Acta Orthop Scand, 64, 59-63.
68. Khan, N, and C Alden (2002). Kidney. In W Haschek, C Rousseux and M Walling (Eds.), Handbook of Toxicologic Pathology, Vol. 2 (pp. 272-274). San Diego, CA: Academic Press.
69. Khan, KN, S Paulson, and K Seibert (1997). Gastrointestinal and renal safety of a specific COX-2 inhibitor versus NSAIDs in dogs. Vet Pathol, 34, 509.
70. Khan, KN, SK Paulson, KM Verburg, JB Lefkowith, and TJ Maziasz (2002). Pharmacology of cyclooxygenase-2 inhibition in the kidney. Kidney Int, 61, 1210-1219.
71. Khan, KN, CM Venturini, RT Bunch, JA Brassard, AT Koki, and DL Morris (1998). Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal anti-inflammatory drug-related nephrotoxicity. Toxicol Pathol, 26, 612-620.
72. Kim, SJ, NA Adams, HS Toma, ML Belair, JE Thorne, WR Green, and DA Jabs (2008). Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina, 28, 595-605.
73. Kim, SM, L Chen, D Mizel, YG Huang, JP Briggs, and J Schnermann (2007). Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol, 292, F415-F422.
74. Lanas, A, J Panes, and JM Pique (2003). Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des, 9, 2253-2266.
75. Lanza, FL, RS Nelson, and BP Greenberg (1983). Effects of fenbufen, indomethacin, naproxen, and placebo on gastric mucosa of normal volunteers. A comparative endoscopic and photographic evaluation. Am J Med, 75, 75-79.
76. Li, JT, ZS Li, and XB Zhan (2003). Experimental study of the safety of the selective COX-2 inhibitor, celecoxib, for gastric mucosa. Chin J Dig Dis, 4, 53-56.
77. Li, X, Y Okada, CC Pilbeam, JA Lorenzo, CR Kennedy, RM Breyer, and LG Raisz (2000). Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology, 141, 2054-2061.
78. Li, X, CC Pilbeam, L Pan, RM Breyer, and LG Raisz (2002). Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. Bone, 30, 567-573.
79. Lin, CH, WS Jee, YF Ma, and RB Setterberg (1995). Early effects of prostaglandin E2 on bone formation and resorption in different bone sites of rats. Bone, 17, 255S-259S.
80. Lindholm, TS, and H Tornkvist (1981). Inhibitory effect on bone formation and calcification exerted by the anti-inflammatory drug ibuprofen. An experimental study on adult rat with fracture. Scand J Rheumatol, 10, 38-42.
81. Linz, W, G Wiemer, P Gohlke, T Unger, and BA Scholkens (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev, 47, 25-49.
82. Lopez, PF, BD Sippy, HM Lambert, AB Thach, and DR Hinton (1996). Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci, 37, 855-868.
83. Lopez-Ovejero, JA, MA Weber, JIM Drayer, JE Sealey, and JH Laragh (1978). Effects of indomethacin alone and during diuretic or beta-adrenergic blockade therapy on blood pressure and the renin system in essential hypertension. Clin Sci Mol Med, 55, 203S-205S.
84. Luna, SP, AC Basílio, PV Steagall, LP Machado, FQ Moutinho, and RK Takahira (2007). Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res, 68, 258-264.
85. Mackay, RJ, TW French, HT Nguyen, and IG Mayhew (1983). Effects of large doses of phenylbutazone administration to horses. Am J Vet Res, 44, 774-780.
86. Mahmud, T, SS Rafi, DL Scott, JM Wrigglesworth, and I Bjarnason (1996). Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum, 39, 1998-2003.
87. Marks, SC, Jr, and S Miller (1988). Local infusion of prostaglandin E1 stimulates mandibular bone formation in vivo. J Oral Pathol, 17, 500-505.
88. Marsolais, D, CH Cote, and J Frenette (2003). Nonsteroidal anti-inflammatory drug reduces neutrophil and macrophage accumulation but does not improve tendon regeneration. Lab Invest, 83, 991-999.
89. Masferrer, JL, A Koki, and K Seibert (1999). COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci, 889, 84-86.
90. Masferrer, JL, KM Leahy, AT Koki, BS Zweifel, SL Settle, BM Woerner, DA Edwards, AG Flickinger, RJ Moore, and K Seibert (2000). Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60, 1306-1311.
91. Mathews, KA (1996). Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats. Can Vet J, 37, 539-545.
92. Mbugua, SW, LA Skoglund, and P Lokken (1989). Effects of phenylbutazone and indomethacin on the post-operative course following experimental orthopaedic surgery in dogs. Acta Vet Scand, 30, 27-35.
93. Meade, EA, WL Smith, and DL DeWitt (1993). Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem, 268, 6610-6614.
94. Meschter, CL, M Gilbert, L Krook, G Maylin, and R Corradino (1990a). The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study. Equine Vet J, 22, 255-263.
95. Meschter, CL, M Gilbert, L Krook, G Maylin, and R Corradino (1990b). The effects of phenylbutazone on the morphology and prostaglandin concentrations of the pyloric mucosa of the equine stomach. Vet Pathol, 27, 244-253.
96. Millichamp, NJ, J Dziezyc, BH Rohde, GC Chiou, and WB Smith (1991). Acute effects of anti-inflammatory drugs on neodymium:yttrium aluminum garnet laser-induced uveitis in dogs. Am J Vet Res, 52, 1279-1284.
97. Morham, SG, R Langenbach, CD Loftin, HF Tiano, N Vouloumanos, JC Jennette, JF Mahler, KD Kluckman, A Ledford, CA Lee, and O Smithies (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 83, 473-482.
98. Muscara, MN, N Vergnolle, F Lovren, CR Triggle, SN Elliott, S Asfaha, and JL Wallace (2000). Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol, 129, 1423-1430.
99. Narita, T, R Sato, N Tomizawa, K Tani, S Komori, and S Hara (2006). Safety of reduced-dosage ketoprofen for long-term oral administration in healthy dogs. Am J Vet Res, 67, 1115-1120.
100. Norrdin, RW, and MS Shih (1988). Systemic effects of prostaglandin E2 on vertebral trabecular remodeling in beagles used in a healing study. Calcif Tissue Int, 42, 363-368.
101. Okada, Y, JA Lorenzo, AM Freeman, M Tomita, SG Morham, LG Raisz, and CC Pilbeam (2000). Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest, 105, 823-832.
102. Okada, Y, C Pilbeam, L Raisz, and Y Tanaka (2003). Role of cyclooxygenase-2 in bone resorption. J UOEH, 25, 185-195.
103. Ono, K, T Akatsu, N Kugai, CC Pilbeam, and LG Raisz (2003). The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone, 33, 798-804.
104. Opay, AL, CR Mouton, JJ Mullins, and KD Mitchell (2006). Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension. Am J Physiol Renal Physiol, 29, F612-8.
105. Pablos, AB, SA Ramalho, B König, Jr, C Furuse, VC de Araújo, and PR Cury (2008). Effect of meloxicam and diclofenac sodium on peri-implant bone healing in rats. J Periodontol, 79, 300-306.
106. Persson, AE, M Salomonsson, P Westerlund, R Greger, E Schlatter, and E Gonzalez (1991). Macula densa cell function. Kidney Int Suppl, 32, S39-S44.
107. Pollmeier, M, C Toulemonde, C Fleishman, and PD Hanson (2006). Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Vet Rec, 159, 547-551.
108. Radi, ZA, and NK Khan (2005). Effects of cyclooxygenases on bone, tendon, and ligament healing. Inflamm Res, 54, 358-366.
109. Radi, ZA, and NK Khan (2006). Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Tox Pathol, 58, 163-173.
110. Radi, ZA, and R Ostroski (2007). Pulmonary and cardiorenal cyclooxygenase-1 (COX-1), -2 (COX-2), and microsomal prostaglandin E synthase- 1 (mPGES-1) and -2 (mPGES-2) expression in a hypertension model. Mediators Inflamm, 2007, 85091.
111. Radi, ZA, and NK Khan (2008). Expression of COX-1, COX-2, iNOS and p38 in human brain with stroke lesions. Int J Pharmacol, 4, 108-113.
112. Radi, ZA, and JA Render (2008). The pathophysiologic role of cycooxygenases in the eye. J Ocular Pharmacol Ther, 24, 141-151.
113. Raekallio, MR, AK Hielm-Björkman, J Kejonen, HM Salonen, and SM Sankari (2006). Evaluation of adverse effects of long-term orally administered carprofen in dogs. J Am Vet Med Assoc, 228, 876-880.
114. Rainsford, KD (1982). An analysis of the gastro-intestinal side-effects of non-steroidal anti-inflammatory drugs, with particular reference to comparative studies in man and laboratory species. Rheumatol Int, 2, 1-10.
115. Raisz, LG (1999). Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage, 7, 419-421.
116. Raisz, LG (2001). Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med, 110 (Suppl 3A). 43S-45S.
117. Reed, S (2002). Nonsteroidal anti-inflammatory drug-induced duodenal ulceration and perforation in a mature rottweiler. Can Vet J, 43, 971-972.
118. Reuter, BK, NM Davies, and JL Wallace (1997). Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology, 112, 109-117.
119. Richter, CM, M Godes, C Wagner, C Maser-Gluth, S Herzfeld, M Dorn, F Priem, T Slowinski, C Bauer, W Schneider, HH Neumayer, A Kurtz, and B Hocher (2004). Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens, 22, 191-198.
120. Ricketts, AP, KM Lundy, and SB Seibel (1998). Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other non-steroidal anti-inflammatory drugs. Am J Vet Res, 59, 1441-1446.
121. Riley, GP, M Cox, RL Harrall, S Clements, and BL Hazleman (2001). Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro. J Hand Surg [Br], 26, 224-228.
122. Ringel, RE, JI Brenner, PJ Haney, JE Burns, AL Moulton, and MA Berman (1982). Prostaglandin-induced periostitis: a complication of long-term PGE1 infusion in an infant with congenital heart disease. Radiology, 142, 657-658.
123. Roudebush, P, and GE Morse (1981). Naproxen toxicosis in a dog. J Am Vet Med Assoc, 179, 805-806.
124. Rodriguez, F, MT Llinas, JD Gonzalez, J Rivera, and FJ Salazar (2000). Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension, 36, 276-281.
125. Ryan, WG, K Moldave, and D Carithers (2006). Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study. Vet Ther, 7, 119-126.
126. Sahloul, MZ, R al-Kiek, P Ivanovich, and SK Mujais (1990). Nonsteroidal anti-inflammatory drugs and antihypertensives. Cooperative malfeasance. Nephron, 56, 345-352.
127. Sakamoto, T, D Soriano, J Nassaralla, TL Murphy, A Oganesian, C Spee, DR Hinton, and SJ Ryan (1995). Effect of intravitreal administration of indomethacin on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol, 113, 222-226.
128. Schalnus, R (2003). Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica, 217, 89-98.
129. Scheiman, JM (1996). NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am, 25, 279-298.
130. Scherkl, R, and HH Frey (1987). Pharmacokinetics of ibuprofen in the dog. J Vet Pharmacol Ther, 10, 261-265.
131. Sellers, RS, PB Senese, and KN Khan (2004). Interspecies differences in the nephrotoxic response to cyclooxygenase inhibition. Drug Chem Toxicol, 27, 111-122.
132. Sennlaub, F, F Valamanesh, A Vazquez-Tello, AM El-Asrar, D Checchin, S Brault, F Gobeil, MH Beauchamp, B Mwaikambo, Y Courtois, K Geboes, DR Varma, P Lachapelle, H Ong, F Behar-Cohen, and S Chemtob (2003). Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation, 108, 198-204.
133. Shih, MS, and RW Norrdin (1986). Effect of prostaglandin E2 on rib fracture healing in beagles: histomorphometric study on periosteum adjacent to the fracture site. Am J Vet Res, 47, 1561-1564.
134. Sigthorsson, G, RJ Simpson, M Walley, A Anthony, R Foster, C Hotz-Behoftsitz, A Palizban, J Pombo, J Watts, SG Morham, and I Bjarnason (2002). COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology, 122, 1913-1923.
135. Simon, AM, and JP O'Connor (2007). Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am, 89, 500-511.
136. Simon, AM, MB Manigrasso, and JP O'Connor (2002). Cyclooxygenase 2 function is essential for bone fracture healing. J Bone Miner Res, 17, 963-976.
137. Somasundaram, S, G Sigthorsson, RJ Simpson, J Watts, M Jacob, IA Tavares, S Rafi, A Roseth, R Foster, AB Price, JM Wrigglesworth, and I Bjarnason (2000). Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther, 14, 639-650.
138. Steagall, PV, FB Mantovani, TH Ferreira, ES Salcedo, FQ Moutinho, and SP Luna (2008). Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther, 30, 218-223.
139. Sun, JS, YH Tsuang, FH Lin, HC Liu, CZ Tsai, and WH Chang (1999). Bone defect healing enhanced by ultrasound stimulation: an in vitro tissue culture model. J Biomed Mater Res, 46, 253-261.
140. Suponitzky, I, and M Weinreb (1998). Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J Endocrinol, 156, 51-57.
141. Suzawa, T, C Miyaura, M Inada, T Maruyama, Y Sugimoto, F Ushikubi, A Ichikawa, S Narumiya, and T Suda (2000). The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology, 141, 1554-1559.
142. Takahashi, K, Y Saishin, Y Saishin, K Mori, A Ando, S Yamamoto, Y Oshima, H Nambu, MB Melia, DP Bingaman, and PA Campochiaro (2003). Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci, 44, 409-415.
143. Takahashi, H, Y Yanagi, Y Tamaki, S Uchida, and K Muranaka (2004). COX-2-selective inhibitor, etodolac, suppresses choroidal neovascularization in a mice model. Biochem Biophys Res Commun, 325, 461-466.
144. Takeuchi, K, A Tanaka, Y Hayashi, and Y Kubo (2004). Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility. Dig Dis Sci, 49, 180-187.
145. Tai, H, C Miyaura, CC Pilbeam, T Tamura, Y Ohsugi, Y Koishihara, N Kubodera, H Kawaguchi, LG Raisz, and T Suda (1997). Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology, 138, 2372-2379.
146. Tanaka, A, H Araki, Y Komoike, S Hase, and K Takeuchi (2001). Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. J Physiol Paris, 95, 21-27.
147. Tanaka, A, H Araki, S Hase, Y Komoike, and K Takeuchi (2002). Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury. Aliment Pharmacol Ther, 16 (Suppl 2). 90-101.
148. Tanaka, A, S Hase, T Miyazawa, R Ohno, and K Takeuchi (2002). Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther, 303, 1248-1254.
149. Tian, XY, Q Zhang, R Zhao, RB Setterberg, QQ Zeng, SJ Iturria, YF Ma, and WS Jee (2008). Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats. Bone., 42, 914-920.
150. Tomida, T, Y Numaguchi, Y Nishimoto, M Tsuzuki, Y Hayashi, H Imai, H Matsui, and K Okumura (2003). Inhibition of COX-2 prevents hypertension and proteinuria associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats. J Hypertens, 21, 601-609.
151. Traub-Dargatz, JL, JJ Bertone, DH Gould, RH Wrigley, MG Weiser, and SD Forney (1988). Chronic flunixin meglumine therapy in foals. Am J Vet Res, 49, 7-12.
152. Tsugawa, K, M Hashizume, S Migou, F Kishihara, H Kawanaka, M Tomikawa, and K Sugimachi (1999). A selective cyclooxygenase-2 inhibitor, NS-398, may improve portal hypertension without inducing gastric mucosal injury. J Gastroenterol Hepatol, 14, 642-651.
153. van Delft, JL, NJ van Haeringen, E Glasius, ER Barthen, and JA Oosterhuis (1987). Comparison of the effects of corticosteroids and indomethacin on the response of the blood-aqueous barrier to injury. Curr Eye Res, 6, 419-425.
154. Wadleigh, DJ, and HR Herschman (1999). Transcriptional regulation of the cyclooxygenase-2 gene by diverse ligands in murine osteoblasts. Biochem Biophys Res Commun, 264, 865-870.
155. Wallace, JL, CM Keenan, and DN Granger (1990). Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol, 259, G462-467.
156. Wallace, JL, W Mcknight, BK Reuter, and N Vergnolle (2000). NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology, 119, 706-714.
157. Wang, JL, HF Cheng, and RC Harris (1999). Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension, 34, 96-101.
158. Wang, JL, HF Cheng, S Shappell, and RC Harris (2000). A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int, 57, 2334-2342.
159. Watanabe, T, K Higuchi, A Kobata, H Nishio, T Tanigawa, M Shiba, K Tominaga, Y Fujiwara, N Oshitani, T Asahara, K Nomoto, K Takeuchi, and T Arakawa (2008). Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut, 57, 181-117.
160. Weinreb, M, M Machwate, N Shir, M Abramovitz, GA Rodan, and S Harada (2001). Expression of the prostaglandin E(2) (PGE(2)) receptor subtype EP(4) and its regulation by PGE(2) in osteoblastic cell lines and adult rat bone tissue. Bone, 28, 275-281.
161. Wen, SF (1997). Nephrotoxicities of nonsteroidal anti-inflammatory drugs. J Formos Med Assoc, 96, 157-171.
162. Wilkinson-Berka, JL (2004). Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des, 10, 3331-3348.
163. Wilkinson-Berka, JL, NS Alousis, DJ Kelly, and RE Gilbert (2003). COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 44, 974-979.
164. Yamada, M, M Kawai, Y Kawai, and Y Mashima (1999). The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res, 19, 300-304.
165. Yamauchi, H, T Iso, J Iwao, and H Iwata (1979). The role of prostaglandins in experimental ocular inflammations. Agents Actions, 9, 280-283.
166. Yang, RS, TK Liu, and SY Lin-Shiau (1993). Increased bone growth by local prostaglandin E2 in rats. Calcif Tissue Int, 52, 57-61.
167. Yang, T, I Singh, H Pham, D Sun, A Smart, JB Schnermann, and JP Briggs (1998). Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol, 274, F481-F489.
168. Yuan, J, GA Murrell, AQ Wei, RC Appleyard, P Del Soldato, and MX Wang
169. Zewde, T, and DL Mattson (2004). Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension, 44, 424-428.
170. Zhang, L, YM Lu, and XY Dong (2004). Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trini-trobenzene sulfonic acid. Chin J Dig Dis, 5, 110-114.
171. Zhang, X, SG Morham, R Langenbach, DA Young, L Xing, BF Boyce, EJ Puzas, RN Rosier, RJ O'Keefe, and EM Schwarz (2001). Evidence for a direct role of cyclooxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res, 16, 660-670.
172. Zhang, X, EM Schwarz, DA Young, JE Puzas, RN Rosier, and RJ OKeefe (2002). Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest, 109, 1405-1415.